OncoMatch/Clinical Trials/NCT06471738
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Is NCT06471738 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Rituximab and Zanubrutinib for ann arbor stage ii follicular lymphoma.
Treatment: Zanubrutinib · Rituximab · Venetoclax — This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Grade: 123a
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) > 1.0 x 10^9/L; Platelet count > 50 x 10^9/L; Hemoglobin ≤ 10 g/dL (for inclusion, if due to lymphoma)
Kidney function
Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula
Liver function
AST and ALT < 3 x ULN; Bilirubin < 1.5 x ULN unless due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
Absolute neutrophil count (ANC) > 1.0 x 10^9/L; Platelet count > 50 x 10^9/L; Prothrombin time (PT)/INR < 1.5 x ULN and PTT (aPTT) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0); Serum AST and ALT < 3 x ULN; Creatinine clearance > 30 ml/min calculated by modified Cockcroft-Gault formula; Bilirubin < 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06471738 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages